Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding

Pharmacogenetics and Genomics

Volumn 18, Issue 1, 2008, Pages 37-43

  Blanco, Gerardo ^a,b   Martínez, Carmen ^a   Ladero, Jose M ^c   Garcia Martin, Elena ^a   Taxonera, Carlos ^c   Gamito, Francisco G ^b   Diaz Rubio, Manuel ^c   Agundez, Jose A G ^a  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b HOSPITAL INFANTA CRISTINA   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Adverse effects; Bleeding; CYP2C8; CYP2C9; Nonsteroidal anti inflammatory drugs

Indexed keywords

ACECLOFENAC; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; DICLOFENAC; DIFLUNISAL; DIPYRONE; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXICAM DERIVATIVE; PARACETAMOL; SALICYLIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRINKING BEHAVIOR; DRUG METABOLISM; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK; SEX DIFFERENCE; SMOKING;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARYL HYDROCARBON HYDROXYLASES; CASE-CONTROL STUDIES; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; RISK ASSESSMENT;

EID: 38949134846     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3282f305a9     Document Type: Article

References (29)

1. Tarone RE, Blot WJ, McLaughlin JK. Nonselective nonaspirin nonsteroidal anti-inflammatory drugs and gastrointestinal bleeding: relative and absolute risk estimates from recent epidemiologic studies. Am J Ther 2004; 11: 17-25.
2. Pilotto A, Franceschi M, Vitale DF, Zaninelli A, Masotti G, Rengo F. Upper gastrointestinal symptoms and therapies in elderly out-patients, users of non-selective NSAID or coxibs. Aliment Pharmacol Ther 2005; 22:147-155.
3. Meyer UA. Pharmacogenetics-five decades of therapeutic lessons from genetic diversity. Nat Rev Genet 2004; 5:669-676.
4. Giacomini KM, Krauss RM, Roden DM, Eichelbaum M, Hayden MR, Nakamura Y. When good drugs go bad. Nature 2007; 446:975-977.
5. Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005; 77:1-16.
6. Martinez C, Blanco G, Ladero JM, Garcia-Martin E, Taxonera C, Gamito FG, et al. Genetic predisposition to acute gastrointestinal bleeding after NSAID use. Br J Pharmacol 2004; 141:205-208.
7. Totah RA, Rettie AE. Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther 2005; 77:341-352.
8. Martinez C, Garcia-Martin E, Blanco G, Gamito FJ, Ladero JM, Agundez JA. The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. Br J Clin Pharmacol 2005; 59:62-69.
9. Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 2007; 132:272-281.
10. Rodrigues AD. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab Dispos 2005; 33: 1567-1575.
11. Garcia-Martin E, Martinez C, Tabares B, Frias J, Agundez JA. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin Pharmacol Ther 2004; 76:119-127.
12. Laine L, Peterson WL. Bleeding peptic ulcer. N Engl J Med 1994; 331:717-727.
13. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001; 11: 597-607.
14. Garcia-Martin E, Martinez C, Ladero JM, Agundez JA. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther 2006; 10:29-40.
15. Bahadur N, Leathart JB, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R, et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol 2002; 64:1579-1589.
16. Nakajima M, Fujiki Y, Noda K, Ohtsuka H, Ohkuni H, Kyo S, et al. Genetic polymorphisms of CYP2C8 in Japanese population. Drug Metab Dispos 2003; 31:687-690.
17. Xie HG, Prasad HC, Kim RB, Stein CM. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 2002; 54:1257-1270.
18. Pértegas Díaz S, Pita Fernández S. Cálculo del poder estadýstico de un estudio. Cad Aten Prim 2003; 10:59-63.
19. Daly AK, Day CP. Candidate gene case-control association studies: advantages and potential pitfalls. Br J Clin Pharmacol 2001; 52:489-499.
20. Brennan P. Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it? Carcinogenesis 2002; 23: 381-387.
21. Yasar U, Lundgren S, Eliasson E, Bennet A, Wiman B, de Faire U, et al. Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem Biophys Res Commun 2002; 299:25-28.
22. Goldstein JA, de Morais SM. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994; 4:285-299.
23. Lee EJ, Williams K, Day R, Graham G, Champion D. Stereoselective disposition of ibuprofen enantiomers in man. Br J Clin Pharmacol 1985; 19:669-674.
24. Vianna-Jorge R, Perini JA, Rondinelli E, Suarez-Kurtz G. CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. Clin Pharmacol Ther 2004; 76:18-26.
25. Perini JA, Vianna-Jorge R, Brogliato AR, Suarez-Kurtz G. Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam. Clin Pharmacol Ther 2005; 78:362-369.
26. Parikh S, Ouedraogo JB, Goldstein JA, Rosenthal PJ, Kroetz DL. Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther 2007; 82:197-203.
27. Garcia-Martin E, Pizarro RM, Martinez C, Gutierrez-Martin Y, Perez G, Jover R, et al. Acquired resistance to the anticancer drug paclitaxel is associated with induction of cytochrome P450 2C8. Pharmacogenomics 2006; 7:575-585.
28. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002; 12:251-263.
29. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 2005; 7:97-104.